Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAlumasc Group Regulatory News (ALU)

Share Price Information for Alumasc Group (ALU)

Share Price is delayed by 15 minutes
Get Live Data
242.50    7.50 (3.19%)
Bid:
240.00
Ask:
245.00
Spread: 5.00 (2.083%)
Market Cap: £87.20m
ALU Live PriceLast checked at - London Stock Exchange

Intraday Alumasc Group Share Chart

Director/PDMR Shareholding

21 Nov 2025 14:17

RNS Number : 5935I
Alumasc Group PLC (The)
21 November 2025
 

 

 

 

The Alumasc Group plc

("the Company")

 

PCA/PDMR dealings

 

21 November 2025

 

The Alumasc Group plc notifies that on 20 November 2025 notification was received that Mrs Luan Leaf, a person closely associated to Mr Michael Leaf, an Executive Director of the Company, exercised 15,000 options over Ordinary Shares of 12.5p each ("Ordinary Shares) at an exercise price of 150p, held under the 2022 Alumasc Employee Option Scheme ("the Option Scheme"). Following the exercise Mrs Leaf sold the 15,000 Ordinary Shares at a price of 287.5p each.

 

Following the above transactions Michael Leaf's total holding (including shares held by his Closely Associated Person) remains unchanged as below:

 

Total holding of

Shares

% of issued share capital

Michael Leaf (and PCAs)

70,946

0.196%

 

 

On the same day Helen Ashton, a PDMR of the Company, exercised 15,000 options held under the 2022 Option Scheme at an exercise price of 150p each. Following this exercise Helen Ashton sold 11,146 Ordinary Shares at a price of 287.5p each to cover associated costs, whilst retaining 3,854 of the new Ordinary Shares. Following the above transactions, Helen Ashton holds 23,671 Ordinary Shares, representing 0.066% of the Company's issued share capital.

 

 

Settlement of the above awards was made from existing Ordinary Shares held by the Employee Benefit Trust.

 

 

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a.

Name

Luan Leaf (PCA to Michael Leaf, Executive Director of the Company)

2.

Reason for the notification

a.

Position/status

Person Closely Associated with Michael Leaf

b.

Initial notification

/Amendment

 

Initial notification

 

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

The Alumasc Group plc

 

b.

LEI

2138002MV11VKZFJ4359

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type

of instrument

Identification code

 

 

Options over Ordinary Shares

Ordinary 12.5p shares

 

 

GB0000280353

b.

Nature of the transaction

 Exercise of Options and Sale of Ordinary Shares

c.

Price(s) and volume(s)

 

Luan Leaf, Person Closely Associated with Michael Leaf

Price(s)

 

Volume(s)

Exercise of Options

£1.50

15,000

Sale of Ordinary Shares

£2.875

15,000

d.

Aggregated information

· Aggregated volume

· Price

 

As above.

e.

Date of the transaction

2025-11-20

f.

Place of the transaction

London Stock Exchange - AIM

5.

Details of the person discharging managerial responsibilities / person closely associated

a.

Name

Helen Ashton

6.

Reason for the notification

a.

Position/status

PDMR

b.

Initial notification

/Amendment

 

Initial notification

 

7.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

The Alumasc Group plc

 

b.

LEI

2138002MV11VKZFJ4359

 

8.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type

of instrument

Identification code

 

 

Options over Ordinary Shares

Ordinary 12.5p shares

 

 

GB0000280353

b.

Nature of the transaction

 Exercise of Options and Sale of Ordinary Shares

c.

Price(s) and volume(s)

 

Helen Ashton PDMR

Price(s)

 

Volume(s)

Exercise of Options

£1.50

15,000

Sale of Ordinary Shares

£2.875

11,146

d.

Aggregated information

· Aggregated volume

· Price

 

As above.

e.

Date of the transaction

2025-11-20

f.

Place of the transaction

London Stock Exchange - AIM

 

 

 

 

 

 

 

Enquiries:

 

The Alumasc Group plc

Paul Hooper (Chief Executive)

Simon Dray (Group Finance Director)

Helen Ashton (Group Company Secretary)

 

+44 (0)1536 383844

 

Peel Hunt (Joint Broker)

Mike Bell

Ed Allsopp

 

 

+44 (0)207 418 8831

Cavendish Capital Markets Ltd (Nominated Adviser and Joint Broker)

Julian Blunt

Edward Whiley

+44 (0)207 220 0500

 

Camarco (Financial PR)

Ginny Pulbrook

Tilly Butcher

 

alumasc@camarco.co.uk

+44 (0)203 757 4992

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHFEWFLFEISEFF
Date   Source Headline
6th May 20261:21 pmRNSHolding(s) in Company
21st Apr 20267:00 amRNSDirector Dealings
20th Apr 20262:37 pmRNSHolding(s) in Company
16th Apr 20267:00 amRNSQ3 Trading Update
1st Apr 20267:00 amRNSConfirmation of CEO appointment
9th Feb 20267:00 amRNS-RMelloMonday Investor Webinar
3rd Feb 20267:00 amRNSInterim Results
15th Jan 20267:00 amRNSDirectorate change
10th Dec 20259:36 amRNSNotice of Half Year Results
21st Nov 20252:17 pmRNSDirector/PDMR Shareholding
7th Nov 202511:22 amRNSDirector/PDMR Shareholding
5th Nov 20252:50 pmRNSDirector/PDMR Shareholding
4th Nov 202511:03 amRNSDirector/PDMR Shareholding
24th Oct 20251:52 pmRNSResult of AGM
24th Oct 20257:00 amRNSAGM Trading Update
23rd Sep 20257:00 amRNSCEO Retirement & 2025 AGM Notice & Annual Accounts
2nd Sep 20257:00 amRNSFinal Results - Unaudited
21st Jul 20257:00 amRNSNotice of FY Results and Investor Presentation
15th Jul 20257:00 amRNSFull Year Trading Update
11th Jun 20253:46 pmRNSDirector/PDMR Shareholding
27th May 20257:00 amRNSAppointment of Non-executive Director
4th Apr 20257:00 amRNS-ROpening new Wade/Gatic building extension
21st Mar 20257:00 amRNSAppointment of Joint Broker
12th Mar 202511:15 amRNSDirector/PDMR Shareholding
4th Feb 20257:00 amRNSHalf-year Results
27th Nov 202412:22 pmRNSNotice of Half Year Results
6th Nov 20241:40 pmRNSDirector/PDMR Shareholding
5th Nov 20248:00 amRNSDirector/PDMR Shareholding
1st Nov 202411:15 amRNSDirector/PDMR Shareholding
29th Oct 20247:00 amRNSDirector/PDMR Shareholding
24th Oct 20241:38 pmRNSResult of AGM
24th Oct 20247:00 amRNSAGM Trading Update
23rd Oct 202412:53 pmRNSDirector/PDMR Shareholding
10th Oct 20247:00 amRNSNotice of Capital Markets Event
4th Oct 20247:00 amRNSDirectorate Change
20th Sep 20242:15 pmRNSNotice of AGM
18th Sep 20242:32 pmRNSDirector/PDMR Shareholding
3rd Sep 20247:00 amRNSFinal Results
25th Jul 20248:00 amRNSNotice of Results
18th Jul 20247:00 amRNSFull Year Trading Update
25th Apr 20249:38 amRNSHolding(s) in Company
27th Feb 202412:31 pmRNSDirector/PDMR Shareholding
14th Feb 20241:01 pmRNSDirector/PDMR Shareholding
6th Feb 20247:00 amRNSInterim results
11th Jan 20247:00 amRNSNotice of Interim Results
3rd Jan 202412:52 pmRNSDirector/PDMR Shareholding
19th Dec 20239:50 amRNSDirector/PDMR Shareholding
18th Dec 20233:17 pmRNSDirector/PDMR Shareholding
18th Dec 20231:23 pmRNSDirector/PDMR Shareholding
18th Dec 20231:10 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.